In preclinical ovarian cancer models, these interventions significantly delay tumor progression and improve survival outcomes, suggesting therapeutic targeting of the IRE1α-XBP1 axis in DCs could potentiate endogenous antitumor immunity and improve immunotherapy efficacy. Here, XBP1 is linked to ovarian cancer.